Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Clinical trial NCT04518046 · COMPLETED
Trial details
- NCT number
- NCT04518046
- Sponsor
- Mirati Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-11
- Primary completion
- 2023-06-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.